Article Text

Download PDFPDF
The effect of travoprost on daytime intraocular pressure in normal tension glaucoma: a randomised controlled trial
  1. G S Ang1,
  2. J P Kersey1,
  3. L Shepstone2,
  4. D C Broadway1
  1. 1
    Norfolk and Norwich University Hospital, Colney Lane, Norwich, UK
  2. 2
    School of Medicine, Health Policy and Practice, University of East Anglia, Norwich, UK
  1. Mr D C Broadway, Department of Ophthalmology, Norfolk and Norwich University Hospital, Colney Lane, Norwich NR4 7UY, UK;{at}


Background/aims: To determine the medium-term effect of travoprost on the daytime intraocular pressure (IOP) of patients with normal tension glaucoma (NTG)

Methods: Newly diagnosed NTG patients underwent baseline, daytime, hourly IOP phasing. Patients were randomised to either treatment or no treatment (control). Treatment comprised once daily topical travoprost 0.004%. After 6 months, the participants underwent their second IOP phasing.

Results: Data from 88 participants were analysed—54 were randomised to treatment and 34 to the control group. The mean duration of treatment was 6 months. The average, maximum and minimum diurnal IOPs for treated patients were statistically significantly lower than for control patients at follow-up (p<0.001). When compared with baseline IOP, the travoprost treated group demonstrated a decrease of 16.1%, 13.5% and 16.7% in the average IOP, maximum IOP, and minimum IOP respectively. Of those treated, about one-third achieved a decrease in average IOP of at least 20%; only about one-tenth achieved a reduction of at least 30%.

Conclusion: Travoprost monotherapy had a sustained hypotensive effect in NTG and achieved a reasonable or good response (>20% reduction in average IOP) in 32.9% of treated eyes. However, in the majority of eyes with NTG, travoprost monotherapy appeared unable to produce the desirable 30% reduction in average IOP.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Funding: The Norwich Glaucoma Research Fund, Norfolk and Norwich University Hospital, Colney Lane, Norwich NR4 7UY, UK.

  • Competing interests: None.

  • Ethics approval: Study approval was obtained from the Huntingdon Local Research Ethics and the East Norfolk and Waveney Research Governance committees.

  • Patient consent: Obtained.

Linked Articles

  • At a glance
    Harminder S Dua Arun D Singh